SCHEMBL9110508

SCHEMBL9110508

O=C(OCc1ccccc1)N(CCCCCO)Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.61
PAX8 Q06710 1/20 0.61
REN P00797 1/20 0.46
HDAC1 Q13547 5/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC3 O15379 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.41
CNR2 P34972 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19018818 1.00 CCR6 (0.61) CCR6PAX8RENHDAC1HDAC6
SCHEMBL15582141 1.00 CCR6 (0.61) CCR6PAX8RENHDAC1HDAC6
SCHEMBL16586897 0.99 CCR6 (0.63) CCR6PAX8RENHDAC1HDAC6
SCHEMBL16585962 0.94 CCR6 (0.60) CCR6PAX8RENHDAC1HDAC6
Benzoic Acid SCHEMBL21326210 0.94 CCR6 (0.55) CCR6PAX8RENHDAC1HDAC6
SCHEMBL14823650 0.88 CCR6 (0.56) CCR6PAX8RENHDAC1HDAC6
SCHEMBL21326213 0.87 CCR6 (0.56) CCR6PAX8RENHDAC1HDAC3
SCHEMBL7864948 0.86 CCR6 (0.62) CCR6PAX8ALDH1A1KMT2ACNR2
SCHEMBL10822929 0.86 CCR6 (0.62) CCR6PAX8ALDH1A1KMT2ACNR2
SCHEMBL8029008 0.86 CCR6 (0.56) CCR6PAX8RENHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282806-A1 CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN JIANGNAN UNIVERSITY (CN) 2025-09-11 US disclosed
CN-118496286-A Chemical synthesis method of vibrio vulnificus organism type 2A serotype O-antigen disaccharide fragment 江南大学 2024-08-16 CN disclosed
US-11603416-B2 Method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide JIANGNAN UNIVERSITY (CN) 2023-03-14 US disclosed
US-11332490-B1 Compounds and methods for treating osteoarthritis ACADEMIA SINICA (TW) 2022-05-17 US disclosed
US-10669353-B2 Preparation method of outer core octasaccharide of Helicobacter pylori lipopolysaccharide JIANGNAN UNIVERSITY (CN) 2020-06-02 US disclosed
US-20190177441-A1 Preparation Method of Outer Core Octasaccharide of Helicobacter Pylori Lipopolysaccharide Max Planck Institute of Colloids and Interfaces (DE) 2019-06-13 US disclosed
US-10174132-B2 Heparan sulfate synthesis UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2019-01-08 US disclosed
US-10052373-B2 Protein and peptide-free synthetic vaccines against Streptococcus pneumoniae type 3 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2018-08-21 US disclosed
EP-3046587-B1 PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) 2018-01-31 EP disclosed
US-20170333545-A1 VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 4 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2017-11-23 US disclosed
EP-3046587-A1 PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) 2016-07-27 EP disclosed
WO-2016091399-A1 VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 4 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-06-16 WO disclosed
US-20160060365-A1 HEPARAN SULFATE SYNTHESIS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2016-03-03 US disclosed
WO-2015040140-A1 PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-03-26 WO disclosed
US-20140234364-A1 TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-08-21 US disclosed
EP-2683401-A1 OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCHARIDE PS-II, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS A VACCINE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-01-15 EP disclosed
US-20130344104-A1 OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCHARIDE PS-II, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS A VACCINE MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2013-12-26 US disclosed
WO-2013041732-A1 TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2013-03-28 WO disclosed
WO-2012119769-A1 OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCHARIDE PS-II, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS A VACCINE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) 2012-09-13 WO disclosed
US-20120142560-A1 HEPARAN SULFATE SYNTHESIS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603416-B2 Method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide DDOST, CSGALNACT1, FUT6 CCR6 2557/4885PAX8 4058/4885REN 1439/4885
US-20170333545-A1 VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 4 NEU4, PA2G4, STT3B CCR6 2151/4885PAX8 2840/4885REN 3740/4885
US-10669353-B2 Preparation method of outer core octasaccharide of Helicobacter pylori lipopolysaccharide FUT6, DDOST, FUT5 CCR6 2726/4885PAX8 2385/4885REN 4193/4885
US-20130344104-A1 OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCHARIDE PS-II, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS A VACCINE DDOST, PSPH, STT3B CCR6 857/4885PAX8 4539/4885REN 4528/4885
US-10174132-B2 Heparan sulfate synthesis HPSE, STT3B, DDOST CCR6 1567/4885PAX8 3929/4885REN 1457/4885
US-20250282806-A1 CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN OGA, DDOST, FUT6 CCR6 3535/4885PAX8 4383/4885REN 3214/4885
US-11332490-B1 Compounds and methods for treating osteoarthritis SULT1E1, STS, ARSA CCR6 3248/4885PAX8 3284/4885REN 1226/4885
US-10052373-B2 Protein and peptide-free synthetic vaccines against Streptococcus pneumoniae type 3 STT3A, DDOST, LGALS3BP CCR6 1338/4885PAX8 3010/4885REN 4154/4885
US-20190177441-A1 Preparation Method of Outer Core Octasaccharide of Helicobacter Pylori Lipopolysaccharide FUT6, DDOST, FUT5 CCR6 2726/4885PAX8 2385/4885REN 4193/4885
US-20160060365-A1 HEPARAN SULFATE SYNTHESIS HPSE, STT3B, DDOST CCR6 1567/4885PAX8 3929/4885REN 1457/4885
US-20140234364-A1 TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS FUT5, DAD1, STT3B CCR6 1872/4885PAX8 4250/4885REN 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.